---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040136"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:54:06.318046+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q2 net loss $18.3M; cash $162M; Phase 3 trial on track for H2 2023 dosing

## Summary
- Net loss $18.3M vs $13.5M in Q2 2022; R&D expenses rose to $15.1M on Phase 3 start-up.
- Cash and marketable securities $162.0M; expected to fund operations into H2 2025.
- Phase 3 trial of bel-sar for choroidal melanoma enrolling; first patient dosing expected H2 2023; commercial material released.
- Key leadership appointments: Bruce Brown (Urologic Oncology), Anthony Daniels (Ocular Oncology), Richard Mountfield (SVP Regulatory).
- Phase 1 NMIBC trial ongoing; data expected 2024; Plan Phase 2 in choroidal metastasis in 2024.

## SEC filing metadata
- accession: 0000950170-23-040136
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/0000950170-23-040136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/aura-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040136
- JSON: https://secwatch.observer/filing/0000950170-23-040136.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040136.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $18.3 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023 was $18.3 million
  - Result: reported results
  source text: On August 9, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017023040136/0000950170-23-040136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.